Login/Register

GXHPC1 (treating liver cirrhosis by using stem cell new drug)

Taiwan
Introduction
GXHPC1 is a novel autologous adipose-derived stem cell therapy for liver cirrhosis (first-in-class). In pre-clinical data, we proved that GXHPC1 can ameliorate hepatic inflammation and reverse liver fibrosis.

According to the data of clinical trial phase I, the outcomes showed GXHPC1 did not cause any safety issues and show a tendency for improvement of liver function, indicating it possesses the potential for helping patients with liver cirrhosis. Currently, GXHPC1 is ongoing in clinical trial phase II (NCT04088058).
Features / strengths
.Advanced technology (first-in-class medicine)
.Leading stem cell medicine for treating liver cirrhosis.
.Intrahepatic (IH) injection
.The outcomes of phase I data have been published. (Cell Transplant. 2019;28(1_suppl):100S-111S. doi:10.1177/0963689719884885)
Specification in detail
Material
Adipose-derived stem cells (ADSCs)
Indication
Liver cirrhosis
Administration
Intrahepatic injection
Product Status
Phase II (NCT04088058)
Location
Taiwan

Clients
Hualien Tzu Chi Hospital , National Taiwan University Hospital , Taipei Municipal Wan Fang Hospital (Managed by Taipei Medical University)

Information
Introduction
GXHPC1 is a novel autologous adipose-derived stem cell therapy for liver cirrhosis (first-in-class). In pre-clinical data, we proved that GXHPC1 can ameliorate hepatic inflammation and reverse liver fibrosis.

According to the data of clinical trial phase I, the outcomes showed GXHPC1 did not cause any safety issues and show a tendency for improvement of liver function, indicating it possesses the potential for helping patients with liver cirrhosis. Currently, GXHPC1 is ongoing in clinical trial phase II (NCT04088058).
Features / strengths
.Advanced technology (first-in-class medicine)
.Leading stem cell medicine for treating liver cirrhosis.
.Intrahepatic (IH) injection
.The outcomes of phase I data have been published. (Cell Transplant. 2019;28(1_suppl):100S-111S. doi:10.1177/0963689719884885)
Specification in detail
Material
Adipose-derived stem cells (ADSCs)
Indication
Liver cirrhosis
Administration
Intrahepatic injection
Product Status
Phase II (NCT04088058)
Location
Taiwan
Clients
Hualien Tzu Chi Hospital , National Taiwan University Hospital , Taipei Municipal Wan Fang Hospital (Managed by Taipei Medical University)

GXHPC1 (treating liver cirrhosis by using stem cell new drug)

Taiwan
Gwo Xi Stem Cell Applied Technology Co., Ltd. Other products
Recommended